Menu
Anticipates risks of tumor escape by targeting over 250 cancer-related antigens driven by relapse mechanism.
Answers huge unmet need in solid tumors : Platform strategy, combining impactful technologies, with standardized steps for a quicker generation of immunotherapy for solid tumors
Preclinical package endoresed with FDA Pre-IND passed.
GMP manufacturing ready.
Top international scientific leader on board & experienced governance in Healthtech industries.
IP by design-platform strategy ; 22 patent granted.
Tailored first-in-class drugs design.
Dynamic immuno-oncology market with mRNA and Personalized Cancer Vaccine.
Ensuring treatment’s availability to a wide population of patient in therapeutic issue.
mCRC preclinical package for the lead candidate, STC-1010, finalized (in-vivo, ex-vivo) endorsed by FDA & FAMHP (EMA). Published in major congress : SITC, AACR, ASCO
Product - GLP, Drugs subsances - GMP Gap Analysis Pre scale-up & Tech transfer - GMP, experienced CDMO
Phase I/II 1L mCRC study synopsis validated (US,BEL,FR)
STC platform design - Granted in Key countries STC-1010 Product - Published
Highly skilled executives and operationals & internationally renowed KOLs on board
Anticipating tumor’s evolution to overpass current limitations
In combination with standard of care
Possible synergy with immunotherapies : They are not necessarily competitors
No other allogeneic vaccine identified to date
MATWIN 2021 award
Finalist 2022
BIOLABS MASTERCLASS
Boston 2022
2022 PRIX GALIEN USA AWARD NOMINEE
"Best startup in the Pharmaceutical or Biotech industry"
ENRICH IN USA 2022 award
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens